[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351809-105":59,"doc-detail-351809-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neuroendocrine-tumours-through-an-epigenetic-lens-emerging-insights-for-diagnosis-and-treatment","Neuroendocrine tumours through an epigenetic lens - Emerging insights for diagnosis and treatment","","Neuroendocrine tumours (NETs) are well-differentiated epithelial neuroendocrine neoplasms that frequently occur in the small intestine, pancreas, and lungs. Originating from hormone-secreting neuroendocrine cells, NETs show malignant transformation with low mutational burden, indicating a possible epigenetic contribution. Growing evidence links epigenetic events to cancer plasticity and tumour initiation, supporting new diagnostic and prognostic advances. This review summarizes current NET diagnosis and management and highlights recent progress on epigenetic regulation and therapeutic opportunities, concluding that additional data are needed to improve outcomes for these rare malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neuroendocrine-tumours-through-an-epigenetic-lens-emerging-insights-for-diagnosis-and-treatment/351809/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neuroendocrine-tumours-through-an-epigenetic-lens-emerging-insights-for-diagnosis-and-treatment/351809.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Where do neuroendocrine tumours (NETs) most commonly develop?","Question",{"text":112,"@type":113},"NETs most commonly develop in the small intestine, pancreas, and lungs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the low mutational burden in NETs suggest?",{"text":117,"@type":113},"The low mutational burden suggests epigenetic mechanisms may be involved in malignant transformation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does epigenetic research support diagnosis, prognosis, and therapy in NETs?",{"text":121,"@type":113},"Recent progress in epigenetic regulation informs diagnosis and prognosis and may enable therapeutic applications using epigenetic-targeting inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351809,1790497030,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10.1111/jne.70211  \nREVIE W A RT ICLE  \nNeuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment  \nVictoria Jacquot 1 | Benjamin Chevalier 1 | Thomas Walter 1,2 | Benjamin Gibert 1 | Maria Ouzounova 1  \n1Gastroenterology and Technologies for Health, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon1, Lyon, France  \n2Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Gastroentérologie etd'Oncologie Digestive, Lyon, France  \nCorrespondence  \nMaria Ouzounova, Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052-CNRS5286-UCBL1, Site Rockefeller, 4ème étage, Escalier D, 8, avenue Rockefeller, 69373 Lyon cedex 08, France. [Email:](Email: maria.ouzounova@lyon.unicancer.fr)[ maria.ouzounova@lyon.unicancer.fr](Email: maria.ouzounova@lyon.unicancer.fr)  \nAbstract  \nNeuroendocrine tumours (NETs) are well-differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes. Their malignant transformation is characterized by low mutational burden, suggesting that epigenetic mechanisms may be at play. Recent understanding of epigenetic events driving cancer cell plasticity and tumour initiation has led to advances in the diagnosis and prognosis of NETs. Here, we provide a brief overview of NETs, including their current diagnosis and management, and present recent progress in understanding the role of epigenetic regulation, highlighting how this may influence NET tumorigenesis and may be used in therapeutic applications. Finally, this literature review emphasizes the need to gather more data on these rare malignancies to improve patient outcome.  \nKEYWOR DS  \nDNA methylation, epigenetic-targeting drugs, neuroendocrine tumors, non-coding RNAs, histone modifications  \n1 | INTRODUCTION  \nNeuroendocrine tumours (NETs) develop from neuroendocrine cells, which are present in all epithelial tissues. These neuroendocrine cells secrete hormones and neurotransmitters into the surrounding tissues/bloodstream in response to neuronal or chemical signals. NETs most commonly develop in the small intestine (siNETs), the pancreas (pNETs) and the lungs.1 Their molecular landscape has been widely characterized over the past 15 years, revealing heterogeneity between locations. Indeed, whereas alterations in MEN1, DAXX/ATRX, and genes involved in the mTOR pathway are frequent in pancreatic NETs, there are no recurrent gene alterations observed in siNETs except CDKN1B mutation in 8 . 5% of siNETs patients2 and only MEN1, ARID1A, and EIF1AX in less than 10% of lung NETs.3–6 Thus, aside from MEN1, there is no strong driver mutation associated with NET  \ntumorigenesis. Hence, we believe that additional mechanisms are implicated in NET development, likely linked to epigenetic processes.  \nSuch epigenetic mechanisms have been reported in the tumorigenesis of various cancers, notably in association with cellular plasticity.7 Among the most studied epigenetic modifications are DNA methylation, histone modifications, and non-coding RNAs. Aside from shedding light on fundamental processes during tumorigenesis, studying epigenetic modifications is also of clinical interest. Indeed, epigenetic modifications are by definition reversible and represent an attractive targeting strategy through the development of epigenetic inhibitors, several of which are already routinely used.8  \nIn this review, we will first synthesize the current state of knowledge of NET biology. We will then examine recent advances in the epigenetic landscape of neuroendocrine neoplasia, with a focus on epigenetic mechanisms implicated in tumorigenesis, their prognostic  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and re","cbCaij2bFGv1r2M2","https://ap.wps.com/l/cbCaij2bFGv1r2M2","pdf",4784791,18,"English","# Abstract\n# Key topics\n## Introduction\n## Neuroendocrine tumours - general features","[{\"question\":\"Where do neuroendocrine tumours (NETs) most commonly develop?\",\"answer\":\"NETs most commonly develop in the small intestine, pancreas, and lungs.\"},{\"question\":\"What does the low mutational burden in NETs suggest?\",\"answer\":\"The low mutational burden suggests epigenetic mechanisms may be involved in malignant transformation.\"},{\"question\":\"How does epigenetic research support diagnosis, prognosis, and therapy in NETs?\",\"answer\":\"Recent progress in epigenetic regulation informs diagnosis and prognosis and may enable therapeutic applications using epigenetic-targeting inhibitors.\"}]","Neuroendocrine tumours through an epigenetic lens - Emerging insights for diagnosis and treatment | PDF",1790096024,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d78f61aa2707fa5fdc369bd4a924122b.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3c000509a78e23e019bd5dd4e00105a.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48df35f5fbbdb8da36b00dc8cca7835d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/caffbf964f8698b32c9bcd08ef7109b2.webp",980,1287]